TheJobsMap
Akero Therapeutics logo

Akero Therapeutics jobs and careers

akerotx.comLinkedIn@akerotx
See 1 open role
1Open roles
$328kHighest listed base pay

About Akero Therapeutics

Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, efruxifermin (EFX), an engineered Fc-FGF21 fusion protein, is currently being evaluated in a Phase 2b clinical trial as a potential treatment for NASH.

Founded in 2017 by Jonathan Young and Tim Rolph.

BiotechnologyLife ScienceTherapeutics
Founded
2017
Employees
11 to 50
Total funding
$951.1M

Leadership

The top of Akero Therapeutics's org chart, with how many people report into each leader.

ACPhoto of Andrew Cheng

Andrew Cheng

President & CEO

48 reports

TRPhoto of Tim Rolph

Tim Rolph

Chief Scientific Officer

3 reports

CYPhoto of Catriona Yale

Catriona Yale

Chief Development Officer

LL

Libette Luce

VP of Regulatory Affairs

1 report

KYPhoto of Kitty Yale

Kitty Yale

EVP And Chief Development Officer

31 reports

SGPhoto of Scott Gangloff

Scott Gangloff

Chief Technical Officer

1 report

MRPhoto of Maribel Rios

Maribel Rios

Senior Executive Coordinator And Office Manager

TRPhoto of Thomas Ross

Thomas Ross

General Counsel

YR

Yasmine Rafidi

Vp, Fp&a

Board

MIPhoto of Mark Iwicki

Mark Iwicki

Board Chair

GWPhoto of Graham Walmsley

Graham Walmsley

Board Director (NASDAQ: AKRO)

JHPhoto of Jane Pritchett Henderson

Jane Pritchett Henderson

Director

JC

Judy Chou

Director

SH

Seth L. Harrison

Director

TH

Tom Heyman

Director